292 related articles for article (PubMed ID: 26735860)
1. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860
[TBL] [Abstract][Full Text] [Related]
2. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
Radwan NA; Ahmed NS
Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
5. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
6. Primary liver carcinoma arising in people younger than 30 years.
Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
[TBL] [Abstract][Full Text] [Related]
7. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.
Pauli-Magnus C; Lang T; Meier Y; Zodan-Marin T; Jung D; Breymann C; Zimmermann R; Kenngott S; Beuers U; Reichel C; Kerb R; Penger A; Meier PJ; Kullak-Ublick GA
Pharmacogenetics; 2004 Feb; 14(2):91-102. PubMed ID: 15077010
[TBL] [Abstract][Full Text] [Related]
8. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
10. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.
Shahid M; Mubeen A; Tse J; Kakar S; Bateman AC; Borger D; Rivera MN; Ting DT; Deshpande V
Am J Surg Pathol; 2015 Jan; 39(1):25-34. PubMed ID: 25353287
[TBL] [Abstract][Full Text] [Related]
11. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver.
de Boer CJ; van Krieken JH; Janssen-van Rhijn CM; Litvinov SV
J Pathol; 1999 Jun; 188(2):201-6. PubMed ID: 10398165
[TBL] [Abstract][Full Text] [Related]
12. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas.
Terada T; Makimoto K; Terayama N; Suzuki Y; Nakanuma Y
J Hepatol; 1996 Jun; 24(6):706-12. PubMed ID: 8835746
[TBL] [Abstract][Full Text] [Related]
13. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.
Cirqueira CS; Felipe-Silva AS; Wakamatsu A; Marins LV; Rocha EC; de Mello ES; Alves VAF
Pathol Oncol Res; 2019 Oct; 25(4):1363-1371. PubMed ID: 29464551
[TBL] [Abstract][Full Text] [Related]
15. Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas.
Zhao CL; Hui Y; Wang LJ; Yang D; Yakirevich E; Mangray S; Huang CK; Lu S
Hum Pathol; 2018 Oct; 80():76-81. PubMed ID: 29883780
[TBL] [Abstract][Full Text] [Related]
16. Hepatobiliary transporter expression in human hepatocellular carcinoma.
Zollner G; Wagner M; Fickert P; Silbert D; Fuchsbichler A; Zatloukal K; Denk H; Trauner M
Liver Int; 2005 Apr; 25(2):367-79. PubMed ID: 15780063
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of hepatocellular carcinoma.
Schlageter M; Terracciano LM; D'Angelo S; Sorrentino P
World J Gastroenterol; 2014 Nov; 20(43):15955-64. PubMed ID: 25473149
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells.
Anthérieu S; Bachour-El Azzi P; Dumont J; Abdel-Razzak Z; Guguen-Guillouzo C; Fromenty B; Robin MA; Guillouzo A
Hepatology; 2013 Apr; 57(4):1518-29. PubMed ID: 23175273
[TBL] [Abstract][Full Text] [Related]
19. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
20. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy.
Keitel V; Vogt C; Häussinger D; Kubitz R
Gastroenterology; 2006 Aug; 131(2):624-9. PubMed ID: 16890614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
